Innovent Reports Second Interim P-III (ORIENT-31) Study Results of Tyvyt (sintilimab) + Byvasda (biosimilar, bevacizumab) for EGFR-Mutated Non-Squamous NSCLC
Shots:
- The P-III (ORIENT-31) study evaluating sintilimab with/out Byvasda (biosimilar, bevacizumab) + CT vs Pt-based CT in 600 patients with EGFR-mutated nsqNSCLC
- In the second interim analysis, m-PFS was 7.2/5.5 & 4.3mos. in arm A (sintilimab + Byvasda & CT)/ arm B (sintilimab & CT) & arm C (CT), the PFS benefit of arm A over arm C was consistent with the first interim analysis & arm B showed clinical improvement in PFS over arm C. The 2EPs of ORR & DoR were both improved in arm B over arm C
- The results were presented at ESMO 2022 & the safety profile was consistent with that observed in prior reported studies of sintilimab & Byvasda without new or unexpected safety signals. The company is conducting 20+ clinical studies of sintilimab globally for cancer
Ref: PRNewswire | Image: Innovent
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
